Trials / Completed
CompletedNCT04728100
LQT and Smartphone/Smartwatch
Smartphone and Smartwatch Based ECG for Patients With Congenital Long QT Syndrome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 111 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Congenital long QT syndrome (LQTS) is a rare genetic disorder characterized by prolongation of the corrected QT interval (QTc) on the electrocardiogram. LQTS is associated with a risk of syncope or sudden death from ventricular arrhythmia. The increase in the duration of the corrected QT interval and / or changes in the morphology of the T wave on the electrocardiogram are markers of an increased risk of sudden death and syncope. Recently, a personal portable 6-lead device (DI, DII, DIII, aVF, aVL and aVR) connected to the patient's smartphone has entered the market (KARDIA MOBILE 6L, AliveCor, Mountain View, CALIFORNIA, USA). The APPLE WATCH Series 6 (Apple, Cupertino, CA, USA) can also record an ECG. If the device is designed to record a single lead (DI), several works have shown that it is possible to record 9 leads (DI, DII, DIII, V1, V2, V3, V4, V5 and V6) by moving simply the device (Spaccarotella CAS et al. JAMA Cardiology 2020). These devices were originally designed to screen for atrial fibrillation, but they produce accurate 6- and 9-lead ECGs and could potentially allow ambulatory ECG monitoring of patients with LQTS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | LQT | Patients with LQT syndrome diagnosis. |
Timeline
- Start date
- 2021-03-22
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
- First posted
- 2021-01-28
- Last updated
- 2023-11-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04728100. Inclusion in this directory is not an endorsement.